DOCSLIB.ORG

Tender Watcher – Drugs: Guangdong Tender Rules Changed Again (For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tender Watcher – Drugs: Guangdong Tender Rules Changed Again (For MORGAN STANLEY RESEARCH ASIA/PACIFIC Morgan Stanley Asia Limited+ Bin Li [email protected] +852 2239 7596 Yolanda Hu [email protected] +852 2848 5649 Isabella Zhao May 19, 2013 [email protected] +852 2848 5887 Tender Watcher – Drugs Guangdong tender rules Tender is a distinctive pricing mechanism for medical products in changed again (for worse?) China and an important lead indicator for product sales and corporate earnings. We launched Tender Watcher to provide updates on a regular basis. Déjà Vu Anhui + Fujian model? The much anticipated Guangdong (GD) provincial drug tender has taken another turn. Based on the newly issued draft guidelines, the GD tender could look like the combination of Anhui, Related Reports Fujian and Chongqing tenders. The good news is our BHC 92 Time to Watch Fujian Tender Price for Non-EDL Drugs industry experts do not believe this current proposal (i.e., August 25, 2011 more focus on price than quality) will be implemented, BHC 93 Key Takeaways from Expert Call on Fujian Drug Tender because this is the first draft for public opinion and will September 27, 2011 likely draw much pushback from the pharma industry, as BHC 98 Jiangsu EDL Tender Shows Positive Signs (Albeit Early) the Anhui model did in 2011. We plan to monitor the November 7, 2011 progress closely, given the importance of Guangdong. BHC 103 Anhui Model Sequel: EDL Marches to Big Hospitals December 6, 2011 What’s new: Guangdong govt. issued the draft TW 10 Tenders May Come In ‘12 guidelines for non-EDL and EDL drugs on May 17, and February 21, 2012 confirmed plans to use the Medicine Exchange for future TW Anhui Non-EDL Tender May Be Modified In Positive Direction tenders (see “Tender Watcher: Surprising twist in February 24, 2012 Guangdong - Bye to tender?”, March 20, 2013). TW Guangdong Non-EDL Tender Signals a Positive Trend April 2, 2012 Key messages from the Guangdong guideline: For TW New EDL Tender Model Emerges from Guangdong non-EDL drugs: 1) No. of groups by formulation is only June 12, 2012 20, similar to Fujian model; 2) five quality layers: TW Anhui Model V.2 – A Positive Transformation patent, original, independent pricing, high-price/ October 9, 2012 high-quality (incl. differentiated drugs), and normal GMP; TW No Major Tenders Before NPC & CPPCC 3) the ceiling price is the average tender price in other March 5, 2013 provinces and the lowest for exclusive drugs; 4) most TW Surprising twist in Guangdong - Bye to tender? importantly, drugs with the lowest bidding price in each March 20, 2013 quality layer will win, similar to Anhui model; 5) the bidding will be conducted every three months. For EDL drugs: 1) Incl. 520 national EDL drugs and local EDL drugs in GD; 2) same purchase prices for grass-roots institutions and higher-tier hospitals; 3) only one group with no quality layer; 4) double envelope system: Total score = 10% of quality + 90% of price. Morgan Stanley does and seeks to do business with Implications on drug and distribution companies: If companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may the current draft is implemented, large drug makers have a conflict of interest that could affect the would see more hits than small ones, as small players objectivity of Morgan Stanley Research. Investors would have better prospects of winning the tender with should consider Morgan Stanley Research as only a low-priced (and low-quality) drugs. Large distributors single factor in making their investment decision. like Sinopharm and Shanghai Pharm would benefit For analyst certification and other important significantly, as all distributors would be required to disclosures, refer to the Disclosure Section, cover all regions in Guangdong province, and hospitals located at the end of this report. += Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be could assign only one distributor for each drug. associated persons of the member and may not be subject to NASD/NYSE restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. MORGAN STANLEY RESEARCH May 19, 2013 Tender Watcher – Drugs Exhibit 1 Ongoing Provincial Non-EDL Drug Tenders Province Tender Stage Latest Status Remarks Anhui 2012 non-EDL tender for announcement stage completed - chemical drugs price cut: ~15% county-level hospitals - TCM price cut: <5% Hubei 2012 non-EDL tender announcement stage batch 2 results released - price cut: ~15% Hainan 2012 non-EDL tender bidding stage information verification - 4 quality layers - 40+ types of formulation - no more than 4 winners for one drug (same generic/formulation/dosage) Shandong 2013 non-EDL tender for pre-tender stage soliciting public opinions for tender guideline - double-envelope system county-level hospitals - 2 quality layers Guangdong 2013 non-EDL tender pre-tender stage soliciting public opinions for tender guideline Hunan 2013 non-EDL tender pre-tender stage soliciting internal opinions for tender guideline (6th draft) Source: Government data, Morgan Stanley Research Exhibit 2 Ongoing Provincial EDL Drug Tenders Province Tender Stage Latest Status Remarks Beijing 2012 EDL tender reviewing stage experts review - incl. new EDL drugs Shaanxi 2013 EDL sppl. tender bidding stage - incl. new EDL drugs Guangdong 2013 EDL tender pre-tender stage soliciting public opinions for tender - incl. new EDL drugs guideline - double envelope: 10% quality + 90% price - one group with no quality layer Source: Government data, Morgan Stanley Research Exhibit 3 Exhibit 4 Upcoming Provincial Non-EDL Drug Tenders Upcoming Provincial EDL Drug Tenders Province Last Tender Period of Last Tender Province Last Tender Period of Last Tender Jiangsu 2009 provincial tender 2010/05/01 - 2011/04/30 Anhui 2010 EDL tender 2010/09/20 - 2011/09/20 Heilongjiang 2009 non-EDL tender 2010/08/01 - 2011/07/31 Hubei 2011 EDL tender 2011/06/08 - 2012/06/07 Zhejiang 2010 provincial tender 2010/10/20 - 2011/10/19 Shanghai 2010 EDL tender 2011/06/10 - 2012/06/09 Hunan 2010 provincial tender 2010/12/31 - 2011/12/31 Heilongjiang 2011 EDL tender 2011/06/26 - 2012/06/25 Henan 2010 provincial tender 2011/01/01 - 2012/01/01 Henan 2011 EDL tender 2011/07/01 - 2012/06/30 Liaoning 2009 provincial tender 2011/01/20 - 2012/01/20 Liaoning 2011 EDL tender 2011/09/10 - 2012/09/09 Shanghai 2010 municipal tender 2011/01/20 - 2012/01/20 Yunnan 2011 EDL tender 2011/09/30 - 2012/09/29 Guizhou 2010 provincial tender 2011/07/25 - 2012/07/24 Hebei 2011 EDL tender 2011/10/01 - 2012/09/30 Beijing 2009 provincial tender 2010/11/30 - 2012/11/30 Jilin 2011 EDL tender 2011/10/24 - 2012/10/23 Hebei 2010 provincial tender 2011/03 - Hunan 2011 EDL tender 2011/12/15 - 2012/12/14 2009 municipal tender Gansu 2011 EDL tender 2011/09/30 - 2012/12/31 Tianjin 2009/03/01 - Source: Government data, Morgan Stanley Research Jiangsu 2011 EDL tender 2012/01/25 - 2013/01/24 Tianjin 2011 EDL tender 2012/03/26 - 2013/03/25 Source: Government data, Morgan Stanley Research 2 MORGAN STANLEY RESEARCH May 19, 2013 Tender Watcher – Drugs Exhibit 5 Provincial Non-EDL Drug Tenders Province Status Execution Status Execution Period Status Execution Period Status Execution Period Anhui county complete2013/01/01 - 2013/12/31 - - -- Beijing - - -- Chongqing Medicine Excha 2011/02/17 - - - Fujian - - completed 2012/01/01 - 2013/06/30 Gansu - - sppl. completed 2012/06/01 - 2013/05/31 - - Guangdong Medicine Excha 1 year - - - - - - Guangxi - - - - completed 2011/04/01 - next tender Guizhou - - - - completed 2011/07/25 - 2012/07/24 3 MORGAN STANLEY RESEARCH May 19, 2013 Tender Watcher – Drugs Exhibit 6 Provincial EDL Drug Tenders 2013 2012 2011 2010 Province Status Execution Status Execution Period Status Execution Period Status Execution Period Anhui - - - - completed 2010/09/20 - 2011/09/20 sppl. 2011/02/18 - 2011/09/20 Beijing in process 1 year - - - - Chongqing - - Medicine Excha 2012/07/11 - completed 2010/07/01 - 2011/06/30 Fujian - - - - completed 2010/05/10 - next tender Gansu - - completed 2011/09/30 - 2012/12/31 - - Guangxi sppl. completed - - - completed 2011/08/01 - next tender Guangdong in process 1 year sppl. completed - completed 2012/07/01 - 2013/06/31 - - Guizhou sppl. completed - sppl. completed 1 year completed 2010/05/18 - 2011/05/17 Hainan - - completed 2012/03/01 - 2013/08/31 - - Hebei - - completed 2011/10/01 - 2012/09/30 completed 2010/07/28 - 2011/09/30 Heilongjiang - - completed 2011/06/26 - 2012/06/25 - - Henan - - completed 2011/07/01 - 2012/06/30 - - Hubei - - completed 2011/06/08 - 2012/06/07 - - Hunan - - completed 2011/12/15 - 2012/12/14 - - Inner Mongolia - - completed 2011/12/16 - 2012/12/15 -- sppl. 2012/07/15 - 2013/07/14 Jiangsu - - completed 2012/01/15 - 2013/01/14 sppl. Jiangxi sppl. completed 2012/12/22 - completed 2011/11/01 - 2012/10/31 - - Jilin - - completed 2011/10/24 - 2012/10/23 completed 2010/11/01 - 2011/10/23 Liaoning - - completed 2011/09/10 - 2012/09/09 - - Ningxia sppl. completed 2012/12/27 - 2013/12/26 sppl. completed 2011/06/20 - 2012/06/19 - - Qinghai sppl. completed 2012/08/30 - 2013/08/30 completed 2011/11/21 - 2012/11/20 - - Shaanxi sppl. In process sppl. completed - - - sppl. completed 2010/12/01 - 2011/12/01 Shandong sppl. completed 1 year completed 2011/07/01 - 2012/06/30 -- sppl.completed 2011/05/01 - 2012/04/30 Shanghai sppl. completed 1 year - - completed 2011/06/10 - 2012/06/09 Shanxi sppl. completed - completed 2011/12/30 - 2012/12/29 completed 2010/02/25 - 2011/02/24 Sichuan - - completed 2011/04/01 - next tender Tianjin - - completed 2012/03/26 - 2013/03/25 completed 2010/04/10 - 2011/03/31 Xinjiang - - completed 2012/01/01 - 2014/01/01 completed Yunnan - - completed 2011/09/30 - 2012/09/29 completed 2010/02/25 - 2011/02/24 Zhejiang - - completed 2011/11/30 - 2012/11/29 - - Tibet -- -- -- Source: Government data, Morgan Stanley Research 4 MORGAN STANLEY RESEARCH May 19, 2013 Tender Watcher – Drugs Disclosure Section The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte.
Load more

Recommended publications
  • Inside This Issue
    1 December 23, 2014 – Issue 122 INSIDE THIS ISSUE China Green Food Expo to be Held in Nanchang China Green Food Expo to be The seventh China Green Food Expo is to be held in Nanchang, Held in Nanchang Jiangxi province. Companies from more than 30 provinces will attend the Expo with thousands of attendees to the event. Jan-Oct China Health Insurance The event is co-held by Ministry of Commerce and Jiangxi local Premium Exceeded CNY 130bn government. CFDA: Cosmeceuticals Should not The Expo tends to promote the economic rise of middle area of Promote Itself as Medicines the country and the opening-up of Jiangxi province. The event will include the food expo and a cooperation seminar joined by Shi Jiazhuang to Crack Down on state-run companies with local food providers and vendors. Illegal Health Food and Cosmetics The Expo mainly features low-carbon industry and green food. It will cover six indoor exhibiting rooms with food companies from Amorepacific Taps Surging more than 30 provinces. Overseas vendors from Australia, Demand for Midrange Beauty America, Russia and Thailand will also bring food to the local Products consumers who will attend the expo. （Source: Food Safety Daily) China Nepstar: A Bitter Pill For Investors Jan-Oct China Health Insurance Premium Exceeded CNY 130bn Herbal Berberine Boosts Brown Fat Activity Premium income of health insurance exceeded CNY 136.656 billion in the first 10 months of this year, growing 45.25% year on year, according to China Insurance Regulatory Commission. Premium income of life insurance companies grew 19.36% year on year.
    [Show full text]
  • Pharma China0409-285.P65
    TM C O N T E N T S ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ ○○○ I s s u e Editorial Mentholatum sues XiAn Meichen over Market Dynamics Brew New Order for trademark infringements 14 Chinese Pharma 2 API/Bulk Drugs 32 News in Focus Huaxing expands capacity of Amoxicillin MOH releases results of the 4th and 6-APA 14 APRIL National Health Service Survey 4 NCPG/DSM likely to build major The Market antibiotic API facility in Changchun 14 2 0 0 9 Data Snaptshot: Chinese OTC Shandong Antibiotics granted Germany healthcare market 5 GMP certification 15 Nicholas Hall reports slower growth Hisun sees profits up sharply in 2008 15 of OTC GI market in China 5 Changzhou Yabang-QH builds new In This Issue Industry News cGMP API plant with help from J&J 15 Chinese pharma industry perfor- Shijiazhuang Pharma receives EDQM MNCs report another year of mance in 2008 and outlook in 2009 5 certification for Vitamin B12 15 sharp revenue growth in China MNCs report another year of sharp India likely to investigate China’s 6-APA 15 Many MNCs experienced growth 20% revenue growth in China 6 MOC issues list of authorized exporters or more in China last year amid global MNCs positions for the huge diabetes of ephedrine drugs 15 slowdown P6 market potential in China 6 Data Snapshot - COS certifications and Harbin Pharma reconsiders Chinese producers likely to emerge DMFs held by Chinese companies 16 overseas IPO as global players of recombinant Chinese API in 2008 – Output and Export In preparation, Harbin Pharmaceutical human insulin 6 Volumes Down 16 Group is working on major and minor M&A is likely to intensify for retail Product and R&D News acquisitions this year P8 pharmacy sector in 2009 7 AOB to initiate clinical trials of TCM drug Pfizer opens new sterile facility Guangzhou introduces online for UI in the U.S.
    [Show full text]
  • China Digest
    China Digest China by numbers Round-up of business news, current issues, • 13,548 meters - combined height of and M&A analysis skyscrapers built in China in 2014 • 3 – number of world’s 10 tallest buildings Q1 2015 built in Wuxi city in 2014 • 7% - share of global freshwater in China In the news … (vs. 20% of world population) • 7 - of China’s ten most polluted cities are Subsidies cut for non-electric vehicles [Auto] in Hebei province The Ministry of Finance reports it is to reduce subsidies for traditional vehicles in • 30,000 - number of TV drama episodes an effort to boost the country’s renewable energy vehicle market. A program to build made in China annually charging infrastructure will also be accelerated. Aside from helping reduce urban pollution levels, the subsidy cut could encourage take-up of electric and hybrid • 14 - number of countries bordering China vehicles and boost domestic manufacturers such as BYD. (Caixin) • 648 million - China's online population • 280 million - number of people in China Growth of China O&G consumption to slow in 2015 [Energy] without safe drinking water China’s oil & gas consumption is expected to see slower growth this year, with falling • $1,831 - President Xi Jinping’s monthly global crude prices providing an opportunity for more energy sector reforms, salary according to the Economic and Technology Research Institute of the country’s • $1.2billion - annual US drug exports to largest O&G producer, China National Petroleum Corp. Chinese oil demand will China grow 3% year-on-year to 534 million metric tons in 2015, compared to growth of • $119.6 billion - China's actual use of 3.3% (to 516 million tons) in 2014, it said.
    [Show full text]
  • 2018 Unaudited Semiannual Report
    BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) Contents Pages Management and Administration 1 Report of the Manager to the Unitholders 2 Statement of Financial Position (Unaudited) 3 Investment Portfolio (Unaudited) 4 – 5 Statement of Movements in Investment Portfolio (Unaudited) 6 – 9 SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) MANAGEMENT AND ADMINISTRATION Manager Directors of the Manager BOCOM International Asset Management Limited TAN Yueheng 9/F, Man Yee Building LI Ying 68 Des Voeux Road Central CHENG Chuange Central Hong Kong Trustee and Registrar Bank of Communications Trustee Limited 1/F, Far East Consortium Building 121 Des Voeux Road Central Central Hong Kong PRC Custodian HSBC Bank (China) Company Limited 33/F, HSBC Building, Shanghai ifc 8 Century Avenue, Pudong Shanghai Legal Counsel to the Manager Deacons 5/F, Alexandra House 18 Chater Road Central Hong Kong Auditor PricewaterhouseCoopers 21/F, Edinburgh Tower 15 Queen’s Road Central Hong Kong - 1 - SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) REPORT OF THE MANAGER TO THE UNITHOLDERS The A-share market under-performance in 1H2018 can be attributed to two main factors: 1) the United States entered an interest rate hike cycle, which caused wide concern about the emerging market’s debt problems.
    [Show full text]
  • China Pharmaceutical Newsletter
    Volume VII 2011 CHINA PHARMACEUTICAL ڵNEWSLETTER З֡Ԛ哦֡ଢ଼рࡗЗ แྼჯ)ཀৄDž዆ᄱᆶ၌ࠅິ SFDA Commissioner Shao Mingli SFDA Deputy Commissioner Wu Zhen of NPC Standing Committee attended the met with new Cuban Ambassador to meets the Head of Iran's Innovation and meeting. Chen Zhu, the Health Minister China On September 29, 2011, Shao Technology Cooperation Center On the & Chairman of the Forum attended the Mingli, Commissioner of SFDA met morning of September 6, 2011, Wu Zhen, forum and delivered a speech. with Mr. ALberto Jesus Blanco Silva, the SFDA Deputy Commissioner, met with the Chen Zhu said in his speech, through new Cuban Ambassador Extraordinary visiting Mr. Hamidreza Amirinia, Head of 30 years of reform and opening up, and Plenipotentiary to China, and his Innovation and Technology Cooperation China's GDP has maintained a 10% entourage in Beijing. The two sides Center of Iran. Both parties exchanged growth in 30 consecutive years, and held in-depth discussions on further views on enhancing mutual exchanges and created an economic miracle. In 2010, strengthening the bilateral cooperation in understanding, and promoting cooperation China's GDP had ranked second in the WKH¿HOGVRIELRORJLFDl products and drug LQWKH¿HOGRIWUDGLWLRQDO&KLQHVHPHGLFLQH world. In the 21st century, the Chinese safety supervision. (September 30, 2011) and biopharmaceuticals. (September 8, 2011) Government pays more attention to social SFDA Deputy Commissioner Wu development, taking the alleviation of SFDA Deputy Commissioner Bian Zhen meets the delegation of MHLW On poverty and improvement of health care, Zhenjia attends the APEC LSIF Drug the morning of August 23, 2011, Wu Zhen, education, housing, and employment, etc.
    [Show full text]
  • VANGUARD INTERNATIONAL EQUITY INDEX FUNDS Form N-Q
    SECURITIES AND EXCHANGE COMMISSION FORM N-Q Quarterly schedule of portfolio holdings of registered management investment company filed on Form N-Q Filing Date: 2018-09-28 | Period of Report: 2018-07-31 SEC Accession No. 0000932471-18-007167 (HTML Version on secdatabase.com) FILER VANGUARD INTERNATIONAL EQUITY INDEX FUNDS Mailing Address Business Address PO BOX 2600 PO BOX 2600 CIK:857489| IRS No.: 000000000 | State of Incorp.:DE | Fiscal Year End: 1031 V26 V26 Type: N-Q | Act: 40 | File No.: 811-05972 | Film No.: 181093806 VALLEY FORGE PA 19482 VALLEY FORGE PA 19482 6106691000 Copyright © 2018 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY Investment Company Act file number: 811-05972 Name of Registrant: VANGUARD INTERNATIONAL EQUITY FUNDS Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482 Name and address of agent for service: Anne E. Robinson, Esquire P.O. Box 876 Valley Forge, PA 19482 Date of fiscal year end: October 31 Date of reporting period: July 31, 2018 Item 1: Schedule of Investments Vanguard Pacific Stock Index Fund Schedule of Investments (unaudited) As of July 31, 2018 Market Value Shares ($000) Common Stocks (99.6%)1 Australia (16.6%) Commonwealth Bank of Australia 1,856,264 103,370 BHP Billiton Ltd. 3,386,626 88,447 Westpac Banking Corp. 3,610,167 79,036 CSL Ltd. 475,901 69,628 Australia & New Zealand Banking Group Ltd.
    [Show full text]
  • Pharmaceuticals in China
    INDUSTRY MARKET RESEARCH FOR BUSINESS LEADERS, STRATEGISTS, DECISION MAKERS CLICK TO VIEW Table of Contents 2 List of Tables & Charts 3 Study Overview 4 Sample Text, Table & Chart 5 Sample Profile, Table & Forecast 6 Order Form 7 About Freedonia, Custom Research, Related Studies, Corporate Use License 8 Pharmaceuticals in China China Industry Study with Forecasts to 2010 & 2015 Study #2024 | February 2006 | $4800 | 240 pages The Freedonia Group 767 Beta Drive www.freedoniagroup.com Cleveland, OH • 44143-2326 • USA Toll Free US Tel: 800.927.5900 or +1 440.684.9600 Fax: +1 440.646.0484 E-mail: [email protected] Study #2024 February 2006 Pharmaceuticals in China $4800 240 Pages China Industry Study with Forecasts to 2010 & 2015 Table of Contents INTRODUCTION Shipments .......................................62 Corticosteroids ............................ 115 Types of Medicines ............................63 Estrogens & Combinations ............. 115 Astragalus ....................................64 Other Hormones ........................... 116 EXECUTIVE SUMMARY Atractylodes ..................................66 Shipments ..................................... 117 Bupleurum ....................................67 Biologicals & Vaccines ........................ 119 MARKET ENVIRONMENT China Root ....................................67 Demand ......................................... 120 General ..............................................4 Cinnamon .....................................68 Vaccines ..................................... 120
    [Show full text]
  • China Nepstar Chain Drugstore Ltd
    +44 20 8123 2220 [email protected] China Nepstar Chain Drugstore Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis https://marketpublishers.com/r/CCAE3DA5C6BBEN.html Date: September 2021 Pages: 50 Price: US$ 499.00 (Single User License) ID: CCAE3DA5C6BBEN Abstracts China Nepstar Chain Drugstore Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between China Nepstar Chain Drugstore Ltd. and its competitors. This provides our Clients with a clear understanding of China Nepstar Chain Drugstore Ltd. position in the Retail Industry. The report contains detailed information about China Nepstar Chain Drugstore Ltd. that gives an unrivalled in-depth knowledge about internal business- environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history. Another part of the report is a SWOT-analysis carried out for China Nepstar Chain Drugstore Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it. The China Nepstar Chain Drugstore Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios China Nepstar Chain Drugstore Ltd.
    [Show full text]
  • 43Gdy6nm9dgg55.Pdf
    Investment Manager: AMP Capital Investors Limited ABN 59 001 777 591 | AFSL 232497 Issuer and Responsible Entity: BetaShares Capital Ltd ABN 78 139 566 868 | AFSL 341181 28 February 2017 Market Announcements Office ASX Limited AMP CAPITAL DYNAMIC MARKETS FUND (HEDGE FUND) (ASX CODE: DMKT) QUARTERLY PORTFOLIO DISCLOSURE We advise that the Fund’s portfolio as at 30 December 2016 comprised the following holdings: Security Weighting (%) Security Weighting (%) ETFs* SPDR S&P/ASX200 Fund 9.82 Vanguard Value ETF 2.09 Vanguard FTSE Emgerging Markets ETF 8.75 Vanguard Materials ETF 1.95 BetaShares FTSE RAFI AU 200 5.18 iShares Global Materials ETF 1.93 iShares Global Financials ETF 3.21 Topix-17 Banks ETF 1.70 Vaneck Vectors Russia ETF 2.74 Lyxor ETF STOXX Europe 600 Banks 1.61 SPDR Bank ETF 2.67 Vanguard Energy ETF 1.61 *Please note underlying ETF exposures are provided below on a weighted consolidated look through basis. AMP Capital Investors Limited 50 Bridge Street Sydney NSW 2000 Australia Client Services 1800 658 404 8.30am-5.30pm | [email protected] ampcapital.com.au For personal use only Important information: This information has been prepared by BetaShares Capital Ltd (ACN 139 566 868 AFS Licence 341181) ("BetaShares") the Responsible Entity and Issuer of the Fund. AMP Capital Investors Limited (“AMP Capital”) (ABN 59 001 777 591, and AFSL 232497) is the investment manager of the Fund and has been appointed by the Responsible Entity to provide investment management and associated services in respect of the Fund. It is general information only and does not take into account any person’s objectives, financial situation or needs.
    [Show full text]
  • Company Report: Sinopharm
    Company Report: Sinopharm Group Co. Ltd. (01099 HK) Kay Mai 麦梓琪 公司报告：国药控股 (01099 HK) +86 755 23976685 [email protected] 国泰君安研究 2 March 2017 PRC's Largest Pharmaceutical Distributor, “Accumulate” 中国最大的医药分销商，“收集” GTJA ResearchGTJA Sinopharm is the largest pharmaceutical distributor and retailer in the Rating: Accumulate PRC, with sustainable above-industry growth. It took about 16.0% of market share in the pharmaceutical distribution industry and approximately 2.7% of market share in retail pharmacy business in 2015, according to the Ministry of 评级： 收集 Commerce in the People's Republic of China ("MOFCOM"). Sinopharm will benefit from further industry consolidation and will 6-18m TP 目标价: HK$39.89 solidify its leading position in for the foreseeable future. We believe recent polices such as the two-invoice system, unannounced Inspections, and stricter 股价： HK$36.550 Share price GSP will drive out small- and medium-sized distributors, which is likely to boost the market share and maintain the above-average growth of the Company. Revenue is estimated to grow by 12.9%, 12.8% and 12.8% YoY to Stock performance 股价表现 RMB256,337 million, RMB289,268 million and RMB326,410 million in respectively, as a result of 1) stable growth of the 50.0 % of return period FY2016-FY2018, 45.0 pharmaceutical distribution segment deriving from the combinational effect of 40.0 market share gaining growth from direct sales as well as the loss in indirect 35.0 30.0 sales triggered by industry consolidation, 2) fast expansion of the retail 25.0 business and its integration impact, and 3) a promising outlook for innovative 20.0 15.0 businesses such as financial leasing.
    [Show full text]
  • Annual Report 2017
    ANNUAL REPORT 2017 (Incorporated in Hong Kong with limited liability) (Stock Code : 00656) PROFIT ATTRIBUTABLE TO OWNERS OF THE PARENT RMB13,161.3 million Intelligence in Action 2017 marked the 25th anniversary of Fosun and our strongest financial year ever. Over these years, being a global company with Chinese roots, we are well-prepared for future opportunities with our strong industrial operations. We are dedicated to pursuing our strategy of “Centered around Family, Deeply Rooted in China, Innovating a Global Happiness Ecosystem”. We have hired some of the very best global talent to execute our customer-to-maker (C2M) strategy. We are fully confident that through Fosun’s core operations, innovative technologies and ONE Fosun ecosystem spanning over 35 million families, our C2M strategy will further advance and create value for our customers. In addition, through our newly launched Youle Customer Loyalty Program (“youlè”), Fosun aims at linking its products and services in our health, happiness and wealth ecosystems to create one-stop solutions for 1 billion families around the world. “A journey of a thousand miles begins with a single step”. In the past 25 years, Fosun has continued to be bold yet humble, building its success with stability and consistency. Looking ahead, we must continue to pursue our C2M strategy, focus on core operations, and develop our pioneering technology and innovation platform so we can become not just a global company with Chinese roots, but a global operator of world-class products and services. Furthermore, Fosun’s senior management and global partners* will step up their efforts to carry out more philanthropic works, with a view to doing more practical and effective initiatives to achieve our mission of helping our family customers live in a healthier, happier and wealthier life.
    [Show full text]
  • Sinopharm Group: 2H14 NDR Takeaways: Margin Expansion To
    Sinopharm Group | March 25, 2015 MORGAN STANLEY RESEARCH March 25, 2015 MORGAN STANLEY ASIA LIMITED+ Yolanda Hu Sinopharm Group [email protected] +852 2848-5649 Bin Li 2H14 NDR Takeaways: Margin Expansion [email protected] +852 2239-7596 Isabella Zhao to Continue [email protected] +852 2848-5887 Industry View Stock Rating Price Target Attractive Overweight HK$34.00 Sinopharm Group ( 1099.HK , 1099 HK ) China Healthcare / China Stock Rating Overweight Sinopharm’s solid sales growth and operating leverage are likely to Industry View Attractive continue in 2015, despite the uncertain policy outlook for the Price target HK$34.00 Up/downside to price target (%) 15 Healthcare industry. We find the stock attractive at 18x our revised Shr price, close (Mar 24, 2015) HK$29.50 2015e EPS. Reiterate OW. 52-Week Range HK$34.50-19.72 Sh out, dil, curr (mn) 2,568 Healthy 2015 sales outlook: Given decelerating GDP growth expected in Mkt cap, curr (mn) Rmb60,695 EV, curr (mn) Rmb78,243 2015, mgmt looks for growth of the end-user market to slow to 12%, and for Avg daily trading value (mn) HK$133 the distribution industry to grow 14-15%. Management remains confident about achieving its sales target of 3-5% above the market average. Fiscal Year Ending 12/14 12/15e 12/16e 12/17e ModelWare EPS (Rmb) 1.11 1.32 1.51 1.70 Margin improvement to continue in 2015, ... This is the first quarter that Prior ModelWare EPS 1.10 1.29 1.44 1.58 (Rmb) Sinopharm has recorded faster profit growth than sales growth, mainly due to: Consensus EPS (Rmb)§ 1.10 1.30 1.55 1.50 1) internal integration; 2) economies of scale; 3) optimizing customer mix Revenue, net (Rmb 200,131 235,469 272,701 313,245 (more direct sales to hospitals), and 4) more focus on the quality of growth.
    [Show full text]